抗高血压药物对脓毒症相关结局的影响:一项基于人群的队列研究
该研究基于韩国国民健康保险服务2003至2013年的样本队列数据库,纳入年龄超过30岁、接受高血压治疗后诊断为脓毒症的4549例患者,比较脓毒症前使用ACEI或ARB、钙通道阻滞剂、噻嗪类三类降压药与30天和90天死亡率的关系。结果发现,脓毒症前1个月内未使用任何降压药的患者30天死亡率为36.8%,高于使用者的32.0%(p<0.001)。与ACEI或ARB使用者(参照组)相比,其他药物使用者的90天死亡风险更高(OR 1.27,95%CI 1.07-1.52)。钙通道阻滞剂或噻嗪类的使用与30天和90天死亡风险无关。钙通道阻滞剂使用与正性肌力药物使用风险降低相关,与ACEI或ARB相比OR为1.23(95%CI 1.05-1.44),与噻嗪类相比OR为1.33(95%CI 1.12-1.58)。
要点
- 脓毒症前1个月内未使用任何降压药者30天死亡率为36.8%,高于使用者32.0%(p<0.001)。
- 与脓毒症前使用ACEI或ARB者相比,使用其他降压药者90天死亡风险更高(OR 1.27,95%CI 1.07-1.52)。
- 脓毒症前使用钙通道阻滞剂或噻嗪类与30天和90天死亡风险无关。
- 钙通道阻滞剂使用与正性肌力药物使用风险降低相关:与ACEI或ARB相比OR 1.23(95%CI 1.05-1.44),与噻嗪类相比OR 1.33(95%CI 1.12-1.58)。
适用人群与场景
- 年龄超过30岁、接受高血压治疗后诊断为脓毒症的患者,数据来自韩国国民健康保险服务2003至2013年样本队列数据库。
研究设计与关键结果
- 研究类型为基于人群的队列研究,共纳入4549例脓毒症前已诊断高血压的患者。
- 脓毒症前1个月内未使用任何降压药者30天死亡率为36.8%,使用者为32.0%(p<0.001)。
- 与脓毒症前使用ACEI或ARB者(参照组)相比,使用其他药物者90天死亡风险更高(OR 1.27,95%CI 1.07-1.52)。
- 钙通道阻滞剂或噻嗪类的使用与30天和90天死亡风险无关。
- 钙通道阻滞剂使用与正性肌力药物使用风险降低相关:与ACEI或ARB相比OR 1.23(95%CI 1.05-1.44),与噻嗪类相比OR 1.33(95%CI 1.12-1.58)。
证据类型、等级与局限
- 证据类型:基于人群的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在高血压合并脓毒症患者中,脓毒症前使用ACEI或ARB与较低的90天死亡风险相关,而钙通道阻滞剂或噻嗪类无此生存获益。
- 尽管钙通道阻滞剂使用与正性肌力药物使用风险降低相关,但作者指出其生存获益并不突出。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Although the effect of antihypertensive agents on sepsis has been studied, evidence for survival benefit was limited in the literature. We investigated differences in sepsis-related outcomes depending on the antihypertensive drugs given prior to sepsis in patients with hypertension.
DESIGN: Population-based cohort study.
SETTING: Sample cohort Database of the National Health Insurance Service from 2003 to 2013 in South Korea.
PATIENTS: Patients over 30 years old who were diagnosed with sepsis after receiving hypertension treatment.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Primary outcomes, 30-day and 90-day mortality rates, were analyzed for differences among three representative antihypertensive medications: angiotensin- converting enzyme inhibitors or angiotensin II receptor blockers, calcium channel blockers, and thiazides. In total, 4,549 patients diagnosed with hypertension prior to hospitalization for sepsis were identified. The 30-day mortality was significantly higher among patients who did not receive any medications within 1 month before sepsis (36.8%) than among patients who did (32.0%; p < 0.001). The risk for 90-days mortality was significantly lower in prior angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker users (reference) than in other drug users (odds ratio, 1.27; 95% CI, 1.07-1.52). There was no difference in the risk for 30-day and 90-day mortality depending on whether calcium channel blockers or thiazides were used. Use of calcium channel blockers was associated with a decreased risk for inotropic agent administration, compared with those of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (odds ratio, 1.23; 95% CI, 1.05-1.44) and thiazides (odds ratio, 1.33; 95% CI, 1.12-1.58).
CONCLUSIONS: In patients with sepsis, lower mortality rate was associated with prior use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers not with use of calcium channel blockers or thiazides. The requirement of inotropic agents was significantly lower in prior use of calcium channel blockers, although the survival benefits were not prominent.
参考来源
- Kim J, Kim YA, Hwangbo B, et al. Effect of Antihypertensive Medications on Sepsis-Related Outcomes: A Population-Based Cohort Study. Crit Care Med. 2019. PMID: 30688717. doi:10.1097/CCM.0000000000003654
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。